Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2093034
Max Phase: Preclinical
Molecular Formula: C16H25ClN4O2
Molecular Weight: 340.86
Molecule Type: Small molecule
Associated Items:
ID: ALA2093034
Max Phase: Preclinical
Molecular Formula: C16H25ClN4O2
Molecular Weight: 340.86
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCN1CCN(C)C[C@H](NC(=O)c2cc(Cl)c(N)cc2OC)C1
Standard InChI: InChI=1S/C16H25ClN4O2/c1-4-21-6-5-20(2)9-11(10-21)19-16(22)12-7-13(17)14(18)8-15(12)23-3/h7-8,11H,4-6,9-10,18H2,1-3H3,(H,19,22)/t11-/m0/s1
Standard InChI Key: ATMCNNNBGDVDQH-NSHDSACASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 340.86 | Molecular Weight (Monoisotopic): 340.1666 | AlogP: 1.30 | #Rotatable Bonds: 4 |
Polar Surface Area: 70.83 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 7.90 | CX LogP: 0.95 | CX LogD: 0.32 |
Aromatic Rings: 1 | Heavy Atoms: 23 | QED Weighted: 0.81 | Np Likeness Score: -1.44 |
1. Hirokawa Y, Morie T, Yamazaki H, Yoshida N, Kato S.. (1998) A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin- 3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors., 8 (6): [PMID:9871571] [10.1016/s0960-894x(98)00078-x] |
Source(1):